a record of success

Clinical Trials

Through clinical trials we have offered new hope to patients with severe eczema. New non-steroid based ointments, which reduce skin inflammation, such as tacrolimus, have now become a mainstay in the treatment of this distressing disease.

Biological Treatments

We have helped research new biological treatments for severe psoriasis. These are now recognised as the most effective treatments for this sometimes devastating condition and have revolutionised the lives of many psoriasis sufferers.

Laboratory Reseach

Our PhD students, are bringing treatments and cures ever closer with laboratory research. Our studies have been published in highly rated scientific journals and have won prizes including best paper at the British Society for Investigative Dermatology.

Clinical Psychology

Our clinical psychologist has undertaken pioneering research into the psychological aspects of eczema and psoriasis to understand the loneliness and distress that so many sufferers experience.

Advanced Training

Our support through grants has enabled dermatologists to undertake advanced training, for example in the development of micrographic surgical techniques for skin cancer, helping hundreds of skin cancer patients.

Overall findings that have been made with help from Dermatrust (a summary of work that has been published over the last 10 years):

  1. We mapped out the kinetics of antigen specific T cell infiltration following MT test in normal and AD patients. The magnitude and cellular composition of the response was followed from day 1 to day 21 post MT. We found that the peak of clinical response (on day 3) and peak cellular response (day 7) are asynchronous.
  2. We observed that lesional and non leasional skin in the AD patients have significant cellular infiltrates compared to normal skin in healthy individuals.
  3. We found that circulating regulatory T cells in AD patients have normal function when tested in vitro.
  4. We found that both effector T cells and regulatory CD4+T cells proliferate and accumulate at the site of MT challenge and that both subsets found in the skin have a memory phenotype.
  5. We found that clinical responses to intradermal challenge with recall antigens (PPD, candida and VZV) are reduced in people over 65 years of age.
  6. The reduced clinical responses in the old individuals correlate with reduced cellular infiltration at the site of antigen challenge but not with the antigen specific proliferative responses in circulating T cells, suggesting there is a skin specific defect in memory response to Ag.
  7. We identified a number of potential reasons that could contribute to reduced responsiveness in old individuals: lack of inflammatory mediators, such as TNF-a, secreted by macrophages and other cells of the innate immune system; lack of endothelial activation precluding T cells migration into the skin; increased proportion of regulatory T cells in the skin of older individuals.